BNIP3, BCL2 interacting protein 3, 664

N. diseases: 158; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 GeneticVariation group BEFREE Under our present experimental conditions, treatment response did not correlate with TP53 or hMLH1 status, but was associated with apoptosis-related genes, most notably BNIP3.Int.J.Cancer (Radiat.Oncol.Invest.)90, 175-185 (2000). 10993958 2000
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 GeneticVariation group BEFREE Under our present experimental conditions, treatment response did not correlate with TP53 or hMLH1 status, but was associated with apoptosis-related genes, most notably BNIP3.Int.J.Cancer (Radiat.Oncol.Invest.)90, 175-185 (2000). 10993958 2000
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.070 AlteredExpression disease LHGDN We found that the gene expression of BNIP3 was up-regulated while ZK1, RAD23B, and HSPD1 were down-regulated during early apoptosis of the hepatoma cell mediated by PRE. 12215374 2002
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.070 GeneticVariation disease BEFREE Among these differentially-expressed genes, the galectin-3, serine/threonine kinase SGK, translation factor eIF-4A, -4B, -3, fibroblast growth factor receptor, and ribosomal protein L35A were up-regulated; the mRNAs of Nip3, decorin, and the insulin-like growth factor binding protein-3 were down-regulated in HCC. 12521301 2002
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE The data show a correlation between high expression of BNip3 in the DCIS cells and a high-grade, necrotic lesion that is likely to be associated with invasive tumour. 14648660 2003
CUI: C0007124
Disease: Noninfiltrating Intraductal Carcinoma
Noninfiltrating Intraductal Carcinoma 		0.020 AlteredExpression disease BEFREE The data show a correlation between high expression of BNip3 in the DCIS cells and a high-grade, necrotic lesion that is likely to be associated with invasive tumour. 14648660 2003
CUI: C0007787
Disease: Transient Ischemic Attack
Transient Ischemic Attack 		0.200 Biomarker disease RGD Nuclear localization of the hypoxia-regulated pro-apoptotic protein BNIP3 after global brain ischemia in the rat hippocampus. 14972662 2004
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.080 PosttranslationalModification disease BEFREE Hypermethylation of the BNIP3 promoter was observed in all BNIP3-negative pancreatic cancer cell lines and eight of 10 pancreatic adenocarcinoma samples. 15289340 2004
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas 		0.070 PosttranslationalModification disease BEFREE Hypermethylation of the BNIP3 promoter was observed in all BNIP3-negative pancreatic cancer cell lines and eight of 10 pancreatic adenocarcinoma samples. 15289340 2004
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.040 Biomarker disease LHGDN Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. 15289340 2004
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.020 AlteredExpression disease BEFREE BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer. 15328198 2004
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms 		0.020 AlteredExpression group LHGDN BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer. 15328198 2004
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.310 PosttranslationalModification disease BEFREE Aberrant methylation of BNIP3 was also detected in 66% of primary colorectal and 49% of primary gastric cancers, but not in normal tissue samples collected from areas adjacent to the tumors. 15709167 2005
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 PosttranslationalModification group BEFREE Aberrant methylation of BNIP3 was also detected in 66% of primary colorectal and 49% of primary gastric cancers, but not in normal tissue samples collected from areas adjacent to the tumors. 15709167 2005
CUI: C0017185
Disease: Gastrointestinal Neoplasms
Gastrointestinal Neoplasms 		0.010 AlteredExpression group LHGDN Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. 15709167 2005
CUI: C0685938
Disease: Malignant neoplasm of gastrointestinal tract
Malignant neoplasm of gastrointestinal tract 		0.010 PosttranslationalModification disease BEFREE Apparently, epigenetic alteration of BNIP3 is a frequent and cancer-specific event, which suggests that inactivation of BNIP3 likely plays a key role in the progression of some gastrointestinal cancers and that it may be a useful molecular target for therapy. 15709167 2005
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.330 PosttranslationalModification disease BEFREE Among primary tumours, methylation of BNIP3 was detected in five of 34 (15%) acute lymphocytic leukaemias, six of 35 (17%) acute myelogenous leukaemias and three of 14 (21%) multiple myelomas. 15756280 2005
CUI: C0023418
Disease: leukemia
leukemia 		0.010 PosttranslationalModification disease BEFREE Among primary tumours, methylation of BNIP3 was detected in five of 34 (15%) acute lymphocytic leukaemias, six of 35 (17%) acute myelogenous leukaemias and three of 14 (21%) multiple myelomas. 15756280 2005
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.080 AlteredExpression disease BEFREE Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. 15837765 2005
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas 		0.070 AlteredExpression disease BEFREE Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. 15837765 2005
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE Loss of BNIP3 expression correlated with poorer survival of patients (8 vs 14 months for BNIP3 negative vs positive tumors). 15856026 2005
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.080 AlteredExpression disease BEFREE BNIP3 mRNA levels were 3.0- and 6.3-fold lower in chronic pancreatitis and pancreatic cancer compared to the normal pancreas, respectively. 15856026 2005
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas 		0.070 AlteredExpression disease BEFREE BNIP3 mRNA levels were 3.0- and 6.3-fold lower in chronic pancreatitis and pancreatic cancer compared to the normal pancreas, respectively. 15856026 2005
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.040 AlteredExpression disease LHGDN Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. 15856026 2005
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.080 AlteredExpression disease BEFREE The expression of BNIP3 was restored by the methyltransferase inhibitor 5-aza-deoxycytidine (5-aza-dC), as was the hypoxia-mediated pancreatic cancer cell death. 15942716 2005